The ratio of individuals with TP53 pathogenic variant is higher among breast cancer patients with premenopausal onset or family history of breast cancer than in those with breast cancer; however, there is no clear basis for considering 31 years as a cut-off. Here, TP53 is linked to breast carcinoma.